The meta- analysis showed a significant increase in plasma adiponectin levels following statin therapy .
Although statins are known to increase the risk for new onset diabetes mellitus , our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression
BACKGROUND AND AIMS The effect of statin therapy on plasma adiponectin levels has not been conclusively studied .
Therefore , we aim ed to evaluate this effect through a systematic review and meta- analysis of available r and omized controlled trials ( RCTs ) .
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.
We investigated the effect of pioglitazone in comparison with and in combination with simvastatin on insulin resistance , plasma adiponectin , postpr and ial plasma glucose , insulin , and intact proinsulin levels in a nondiabetic population at cardiovascular risk . One hundred twenty-five nondiabetic patients at cardiovascular risk were r and omized to pioglitazone ( PIO ) , pioglitazone and simvastatin ( PIO/SIM ) , or simvastatin ( SIM ) treatments . Blood sample s were taken for the measurement of adiponectin and lipid levels . In addition , an oral glucose load with the measurements of glucose , insulin , and intact proinsulin levels was performed . Adiponectin levels increased from 14.0+/-8.2 to 27.6+/-14.5 microg/mL ( P<.0001 ) during PIO treatment and from 11.7+/-10.0 to 26.7+/-15.7 microg/mL ( P<.0001 ) during PIO/SIM treatment . A decrease in adiponectin levels from 15.5+/-12.7 to 11.6+/-7.0 microg/mL ( P<.05 ) was observed during SIM treatment . Although fasting intact proinsulin levels remained unchanged , the increase in postpr and ial intact proinsulin levels could be reduced from 29.5+/-21.4 to 22.1+/-17.5 pmol/L ( P<.01 ) during PIO treatment and from 24.3+/-27.4 to 21.1+/-16.5 mmol/L ( P<.05 ) during PIO/SIM treatment . Lipid parameters improved during SIM treatment but not during PIO treatment . Combined treatment with PIO/SIM was superior in improving overall cardiovascular risk profile than every single drug
The meta- analysis showed a significant increase in plasma adiponectin levels following statin therapy .
Although statins are known to increase the risk for new onset diabetes mellitus , our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression
BACKGROUND AND AIMS The effect of statin therapy on plasma adiponectin levels has not been conclusively studied .
Therefore , we aim ed to evaluate this effect through a systematic review and meta- analysis of available r and omized controlled trials ( RCTs ) .